Clinical genitourinary cancer最新文献

{"title":"Evaluation of the Effects of Enzalutamide and Abiraterone Acetate on Sarcopenia in Metastatic Castration-Sensitive Prostate Cancer","authors":"Cevat İlteriş Kıkılı ,&nbsp;Maide Müreva ,&nbsp;Caner Kapar ,&nbsp;Bahadır Köylü ,&nbsp;Fatih Kemik ,&nbsp;Feyyaz Hazar Yağmur ,&nbsp;Fatih Selçukbiricik ,&nbsp;Ercan İnci ,&nbsp;Deniz Tural","doi":"10.1016/j.clgc.2025.102388","DOIUrl":"10.1016/j.clgc.2025.102388","url":null,"abstract":"<div><h3>Background</h3><div>Sarcopenia is associated with worse prognosis and higher mortality in various solid tumors. We aim to evaluate the impact of enzalutamide and abiraterone acetate on sarcopenia in patients with metastatic castration-sensitive prostate cancer.</div></div><div><h3>Materials and Methods</h3><div>The skeletal muscle indexes (SMI, cm²/m²) were calculated from pre-treatment and 12th-month CT scans. Patients were categorized into sarcopenic and non-sarcopenic groups based on the predefined SMI and body mass index cut-off values. Baseline and 12th-month SMI values together with percentages of sarcopenic patients were compared between the enzalutamide and abiraterone acetate groups. Radiological progression-free survival (rPFS) and overall survival (OS) were also compared between sarcopenic and non-sarcopenic patients.</div></div><div><h3>Results</h3><div>We included 19 patients receiving enzalutamide and 30 patients receiving abiraterone acetate. In the enzalutamide group, SMI decreased significantly from pre-treatment to the 12th month (median ΔSMI: −3.1 cm²/m², <em>P</em> = .004). In the abiraterone acetate group, SMI declined significantly over the same period (median ΔSMI: −4.1 cm²/m², <em>P</em> = .001). There were no significant differences in SMI changes and sarcopenia rates between two groups. Median rPFS was 29 months in the pre-treatment sarcopenic group and 37 months in the non-sarcopenic group (HR = 2.38 [95% CI, 0.54-10.41], <em>P</em> = .24). Median OS was 33 months in the sarcopenic group and 47 months in the non-sarcopenic group (HR = 1.94 [95% CI, 0.42-9.03], <em>P</em> = .38).</div></div><div><h3>Conclusion</h3><div>Both enzalutamide and abiraterone acetate significantly reduces SMI values following a 12-month treatment period. Despite a trend toward shorter rPFS and OS in sarcopenic patients, the differences did not reach statistical significance.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102388"},"PeriodicalIF":2.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Size Predict Aggressiveness?: Exploring Sporadic Multifocal Tumors in a 10-Year Retrospective Analysis","authors":"Felicia L. Pasadyn ,&nbsp;Dongling Wu ,&nbsp;Shavy Nagpal ,&nbsp;Fang-Ming Deng ,&nbsp;Rozalba Gogaj ,&nbsp;William C. Huang","doi":"10.1016/j.clgc.2025.102387","DOIUrl":"10.1016/j.clgc.2025.102387","url":null,"abstract":"<div><h3>Introduction and Objective</h3><div>For localized kidney tumors, size and growth kinetics generally predict malignant potential. Thus, for patients with multifocal renal masses, treatment priority often revolves around the largest or index tumor first. We reviewed our kidney surgery database to examine histologic concordance of sporadic multifocal renal tumors and to determine if size is also the greatest determinant of tumor aggressiveness.</div></div><div><h3>Methods</h3><div>We conducted a retrospective chart review at a tertiary referral center of 1983 patients undergoing nephrectomy (radical and partial) from January 2010 to December 2019. We identified 138 patients with multifocal renal masses (<em>n</em> = 138). Surgical pathology parameters, including tumor size, TNM grading, and staging, were collected through electronic medical records. Patients with syndromic diseases were excluded (<em>n</em> = 10), resulting in a total sample of 128 patients with sporadic multifocal tumors. Overall, the sample included 307 tumors total, with a mean number of 2.4 lesions per patient.</div></div><div><h3>Results</h3><div>About 128 patients (6.45%) had sporadic multifocal renal tumors. Among these, 82 out of 128 (64%) had concordant histologic subtypes, while 46 out of 128 (36%) had discordant histology. In 99 patients (77.3%), the index tumor demonstrated a more aggressive histology. There were 29 patients (22.6%) with a benign or less aggressive index tumor. Among those, 21 patients (16%) had a benign index tumor, 5 (24%) of which had a malignant secondary tumor.</div></div><div><h3>Conclusion</h3><div>Multifocal tumors frequently have discordant histology. While size tends to predict oncologic risk, many patients harbor more aggressive disease in nonindex lesions, highlighting the limitations of relying on size alone for managing sporadic multifocal RCC.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 5","pages":"Article 102387"},"PeriodicalIF":2.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144596517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma","authors":"Emre Yekedüz ,&nbsp;Martin Zarba ,&nbsp;Eddy Saad ,&nbsp;Razane El Hajj Chehade ,&nbsp;Marc Eid ,&nbsp;Renee Maria Saliby ,&nbsp;Clara Steiner ,&nbsp;Marc Machaalani ,&nbsp;Rashad Nawfal ,&nbsp;Karl Semaan ,&nbsp;Yüksel Ürün ,&nbsp;Daniel Y.C. Heng ,&nbsp;Toni K. Choueiri","doi":"10.1016/j.clgc.2025.102385","DOIUrl":"10.1016/j.clgc.2025.102385","url":null,"abstract":"<div><h3>Background</h3><div>Comorbid conditions complicate the care of patients with cancer and frequently cause exclusion of patients from clinical trials.</div></div><div><h3>Methods</h3><div>Data from patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitor (ICI)-based combinations in the first line setting were collected. The comorbidity burden was assessed at baseline by using the age-adjusted Charlson Comorbidity Index (CCI). Patients were stratified into 2 groups to predict overall survival (OS) through maximally selected rank statistics. The primary outcomes were time to treatment failure (TTF) and OS. The secondary outcome was the rate of adverse events (AEs) leading to dose reduction or treatment discontinuation.</div></div><div><h3>Results</h3><div>A total of 304 patients were included. Most patients were male (73%), had clear cell RCC (91.4%), and were treated with nivolumab + ipilimumab (53.6%). The most common comorbidities were diabetes (18.4%), followed by previous myocardial infarction (12.8%), chronic kidney disease (6.6%), and chronic pulmonary disease (5.6%). After adjusting for baseline prognostic factors in mRCC including the International mRCC Database Consortium (IMDC) risk, TTF (Hazard Ratio [HR], 1.51, 95% Confidence Interval [CI], 1.09-2.10, <em>P</em> <em>=</em> .013) and OS (HR: 1.98, 95% CI, 1.33-2.94, <em>P</em> <em>=</em> .001) were worse in the CCI-high group vs. the CCI-low group. The rates of AEs leading to dose reduction or treatment discontinuation were comparable between the 2 groups.</div></div><div><h3>Conclusions</h3><div>Despite similar rates of AEs leading to dose reduction or treatment discontinuation, a high comorbidity burden is associated with worse outcomes in patients with mRCC treated with first-line ICI-based therapies. Our study underscores the necessity for a multidimensional approach to assess the comorbidity burden in patients with mRCC receiving ICI-based combinations.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102385"},"PeriodicalIF":2.3,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Gleason, Stage and Age on Surgery and Radiotherapy in Prostate Cancer Patients in Northern Italy","authors":"Lucia Mangone ,&nbsp;Francesco Marinelli ,&nbsp;Isabella Bisceglia ,&nbsp;Angelina Filice ,&nbsp;Maria Barbara Braghiroli ,&nbsp;Francesca Roncaglia ,&nbsp;Andrea Palicelli ,&nbsp;Fortunato Morabito ,&nbsp;Antonino Neri ,&nbsp;Roberto Sabbatini ,&nbsp;Cinzia Iotti ,&nbsp;Carmine Pinto","doi":"10.1016/j.clgc.2025.102383","DOIUrl":"10.1016/j.clgc.2025.102383","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of prostate cancer is increasing due to the aging and early diagnosis. This study aims to evaluate the influence of Gleason, stage and age on surgery and radiotherapy.</div></div><div><h3>Methods</h3><div>In a province of northern Italy were analyzed 1381 prostate cancers diagnosed between 2018 and 2022, focusing on trends in age, stage, Gleason and treatment.</div></div><div><h3>Results</h3><div>Over the study period, there was slight a decline in stage I (39%, 42%, 36%, 28%, 38%) and Gleason 6 (26%, 28%, 28%, 18%, 26%), along with an increase in stage IV (13%, 13%, 15%, 20%, 16%) and Gleason 8-10 (20%, 21%, 21%, 26%, and 28%). Surgery and radiation therapy remained constant at 34% and 40%, respectively. The likelihood of receiving surgery decreased in patients aged 70-79 [OR 0.35; 0.21-0.58] and 80+ [OR 0.03; 0.02-0.07] and increased in Gleason 7 [OR 1.83; 1.27-2.65] and stage II [OR 3.89; 2.74-5.51] and III [OR 9.77; 6.34-15.05]. The possibility of receiving radiotherapy increases in patients aged 70-79 [OR 2.85; 1.75-4.65] and 80+ [OR 2.11; 1.24-3.60] and in patients with Gleason 7 [OR 1.95; 1.42-2.68] and 8-10 [OR 2.95; 1.96-4.46].</div></div><div><h3>Conclusions</h3><div>During the period there was a slight shift toward more aggressive prostate cancers, but treatments remained stable.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102383"},"PeriodicalIF":2.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project","authors":"Jakub Kucharz ,&nbsp;Alexandr Poprach ,&nbsp;Bożena Sikora-Kupis ,&nbsp;Marta Darewicz ,&nbsp;Piotr Domański ,&nbsp;Monika Bezděková ,&nbsp;Ivana Koloušková ,&nbsp;Eva Kolaríková ,&nbsp;Jindrich Kopecky ,&nbsp;Hana Studentova ,&nbsp;Ondrej Fiala ,&nbsp;Igor Richter ,&nbsp;Michal Lacek ,&nbsp;Tomas Buchler ,&nbsp;Alvaro Pinto","doi":"10.1016/j.clgc.2025.102382","DOIUrl":"10.1016/j.clgc.2025.102382","url":null,"abstract":"<div><h3>Introduction</h3><div>The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland</div></div><div><h3>Methods</h3><div>Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest.</div></div><div><h3>Results</h3><div>We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3+4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis.</div></div><div><h3>Conclusions</h3><div>In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102382"},"PeriodicalIF":2.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144489922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-Analysis","authors":"Susu Zhou ,&nbsp;Parissa Alerasool ,&nbsp;Noriko Kishi ,&nbsp;Che-Kai Tsao","doi":"10.1016/j.clgc.2025.102380","DOIUrl":"10.1016/j.clgc.2025.102380","url":null,"abstract":"<div><h3>Introduction</h3><div>With the expanded approval of androgen receptor axis-targeted (ARAT) agents, clinicians now have more treatment options to offer patients with metastatic hormone-sensitive prostate cancer (mHSPC). Uncertainty remains as to whether older population could benefit similarly from these intensification treatment options.</div></div><div><h3>Patients and Methods</h3><div>A systematic database search was performed for randomized controlled trials (RCTs) evaluating the efficacy of androgen deprivation therapy (ADT) in combination with ARAT agents and/or docetaxel in older patients (aged ≥ 70 or 75 years) with mHSPC. The primary endpoint was overall survival (OS). Indirect comparisons of available treatment options were estimated using a random-effects network meta-analysis.</div></div><div><h3>Results</h3><div>A total of 11 RCTs were eligible. In comparison with ADT alone or ADT + docetaxel doublet, darolutamide + ADT + docetaxel showed a significant OS benefit, with hazard ratios (HRs) of 0.47 (95% confidence interval [CI]: 0.28-0.77) and 0.61 (95% CI, 0.40-0.93), respectively. However, another triplet (abiraterone + ADT + docetaxel) failed to demonstrate a statistically significant OS benefit, with HRs of 0.61 (95% CI, 0.37-1.02) and 0.80 (95% CI, 0.52-1.24), respectively. Triplet therapies comprising darolutamide and abiraterone ranked first and second, with <em>P</em> score of .90 and .67, respectively, followed by darolutamide + ADT (0.61), apalutamide + ADT (0.60), enzalutamide + ADT (0.56), ADT + docetaxel (0.40), abiraterone + ADT (0.20) and ADT alone (0.06). Furthermore, our data suggest an additional benefit from adding docetaxel as a component of doublet and triplet therapies for older men with mHSPC.</div></div><div><h3>Conclusion</h3><div>In older patients with mHSPC, triplet therapy comprising darolutamide, ADT, and docetaxel demonstrated the most pronounced OS benefit and ranked highest among currently available treatment options. Further studies are needed to explore the specific toxicities associated with the triplet regimen in this population to better balance oncologic benefits with treatment-related toxicities when making treatment decision.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102380"},"PeriodicalIF":2.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid Use in Patients With Testicular Cancer: Patterns and Risk Factors","authors":"Siddharth Marthi ,&nbsp;Gregory Palmateer ,&nbsp;Dattatraya Patil,&nbsp;Talia A. Helman,&nbsp;Edouard Nicaise,&nbsp;Taylor A. Goodstein,&nbsp;Kenneth Ogan,&nbsp;Vikram M. Narayan,&nbsp;Viraj A. Master,&nbsp;Mohammad Hajiha,&nbsp;Shreyas S. Joshi","doi":"10.1016/j.clgc.2025.102381","DOIUrl":"10.1016/j.clgc.2025.102381","url":null,"abstract":"<div><h3>Introduction</h3><div>Prescription opioid use is a gateway to chronic dependence and associated morbidity and mortality. Research has demonstrated that men receiving narcotics after urologic surgery are at increased risk of persistent opioid use. However, factors associated with persistent use in testicular cancer patients specifically are poorly understood.</div></div><div><h3>Materials and methods</h3><div>The Truven Marketscan database was queried for patients with testicular cancer who underwent orchiectomy between 2009 and 2021. Patients who were under 18 years old, lacked insurance coverage during the study period, filled opioid prescriptions 3 months prior to orchiectomy, or had prior opioid use disorder diagnoses were excluded. Subgroup analysis was performed by receipt of advanced treatment, defined as chemotherapy and/or retroperitoneal lymph node dissection (RPLND). Opioid exposure was defined as receipt of ≥ 1 opioid prescriptions within 30 days of last treatment. Among those who underwent advanced treatment, pretreatment opioid use over the cohort median in oral morphine equivalents (OME) was included in the definition of opioid exposure. Multivariable logistic regression was used to identify risk factors associated with our primary outcome: ≥ 1 filled opioid prescription between 31 to 90 days and 91 to 180 days after last treatment.</div></div><div><h3>Results</h3><div>Of 5409 total patients, 2115 (39.1%) underwent advanced treatment: 1697 (31.4%) chemotherapy, 185 (3.4%) RPLND, and 223 (4.3%) chemotherapy and RPLND (combination). Opioid exposure was associated with a filled opioid prescription at 31 to 90 (OR 4.67) and 91 to 180 days (OR 4.74, both <em>P</em> &lt; .001) after last treatment. On multivariate analysis, chemotherapy and combination therapy, but not RPLND alone, were independently associated with opioid use at 31 to 180 days post-treatment (<em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>Testicular cancer patients who received opioid prescriptions after orchiectomy were more likely to require additional opioid prescriptions 31 to 180 days after treatment. Advanced treatment with chemotherapy alone or combined with RPLND, but not RPLND alone, increased the opioid dependence.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102381"},"PeriodicalIF":2.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Severity of Prostate Cancer Presentation in an Appalachian Cohort Compared to National Data","authors":"Marvin A. Simpkins,&nbsp;Garrett Douglas,&nbsp;Emily Yablonsky,&nbsp;Lawrence Wyner,&nbsp;Justyn Blankenship","doi":"10.1016/j.clgc.2025.102375","DOIUrl":"10.1016/j.clgc.2025.102375","url":null,"abstract":"<div><h3>Background</h3><div>Prostate cancer is the second leading cause of cancer death among American men, with known disparities by geography, socioeconomic status, and access to care. Data on prostate cancer presentation in Appalachia are scarce.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 160 first‐time transrectal ultrasound‐guided prostate biopsies from 2022 to 2024 at a single Appalachian institution and compared them to 8776 positive biopsies from the PLCO trial. Gleason scores were grouped as 1 (≤ 6), 2/3 (7), 4 (8), and 5 (≥ 9). We used chi‐square tests to compare grade distributions and PSA categories (&lt; 4, 4-10, 10-20, &gt; 20 ng/mL), Wilcoxon rank‐sum tests for age and median PSA by grade, and sequential logistic regression (unadjusted; +age; +PSA+age) to identify independent predictors of Appalachian cohort membership.</div></div><div><h3>Results</h3><div>Appalachian patients were more likely to present with Grade 4 (19.1% vs. 7.9%) and Grade 5 disease (10.1% vs. 5.0%; χ² = 49.2, <em>P</em> &lt; .001) and had older median age (e.g., Grade 1: 66 vs. 63 years, <em>P</em> = .0033) and higher median PSA (e.g., Grade 1: 8.6 vs. 5.7 ng/mL, <em>P</em> = .0001). PSA category distribution also differed (χ² = 44.8, <em>P</em> &lt; .001). In fully adjusted models, Grade 4 (OR 2.54, <em>P</em> = .002) and Grade 5 (OR 2.80, <em>P</em> = .002) remained independent predictors of Appalachian cohort membership, while PSA was not (<em>P</em> = .280).</div></div><div><h3>Conclusions</h3><div>Appalachian patients exhibit a disproportionately high prevalence of advanced‐grade prostate cancer that persists after accounting for age and PSA. Tailored, region-specific strategies are needed to enhance early detection and reduce persistent disparities in care.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102375"},"PeriodicalIF":2.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidences of Secondary Malignancies After Androgen Deprivation Therapy for Prostate Cancer","authors":"Junghoon Lee ,&nbsp;Min Chul Cho ,&nbsp;Hyeon Jeong ,&nbsp;Hwancheol Son ,&nbsp;Sangjun Yoo","doi":"10.1016/j.clgc.2025.102379","DOIUrl":"10.1016/j.clgc.2025.102379","url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to assess the effects of ADT on the incidence of secondary malignancies in patients with prostate cancer.</div></div><div><h3>Methods</h3><div>Prostate cancer patients who initially treated with ADT from 2009 were included and followed up until 2019. We additionally included female patients, male patients without prostate cancer, and male patients with prostate cancer who did not undergo ADT to build comparison. A 1:1:1:1 match based on age was performed, and 55,865 individuals from each group were selected for analysis.</div></div><div><h3>Results</h3><div>The incidence of common cancers was compared between the groups. All cancers, except thyroid and breast cancers, were more common in men than women. All cancers were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. After ADT, the incidences of thyroid and breast cancers increased, whereas the incidences of liver and pancreatic cancers decreased. In the multivariate analysis, all types of cancer were more common in men with prostate cancer than in men without prostate cancer, regardless of ADT. Among these, the incidence of liver and pancreatic cancers significantly decreased after ADT.</div></div><div><h3>Conclusion</h3><div>The incidence of several secondary malignancies was affected not only by sex but also by prostate cancer diagnosis and ADT. Although further studies are required, these data could be important for health checkups and the management of prostate cancer survivors, especially prostate cancer patients who have been treated with ADT.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102379"},"PeriodicalIF":2.3,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin","authors":"Simon U. Engelmann ,&nbsp;Christoph Pickl ,&nbsp;Maximilian Haas ,&nbsp;Felix Kasparbauer ,&nbsp;Emily Rinderknecht ,&nbsp;Sebastian Kälble ,&nbsp;Bas W.G. van Rhijn ,&nbsp;Peter J. Siska ,&nbsp;Sonja-Maria Decking ,&nbsp;Kathrin Renner ,&nbsp;Renate Pichler ,&nbsp;Maximilian Burger ,&nbsp;Miodrag Gužvić ,&nbsp;Roman Mayr","doi":"10.1016/j.clgc.2025.102378","DOIUrl":"10.1016/j.clgc.2025.102378","url":null,"abstract":"<div><h3>Background</h3><div>Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue.</div></div><div><h3>Methods</h3><div>In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA.</div></div><div><h3>Results</h3><div>Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; <em>P</em> = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; <em>P</em> = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all <em>P</em> &lt; .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage (<em>P</em> &lt; .01).</div></div><div><h3>Conclusions</h3><div>Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102378"},"PeriodicalIF":2.3,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}